Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: An analysis based on data in the European Blood and Marrow Transplantation registry

Haematologica

Volumn 93, Issue 12, 2008, Pages 1837-1842

  Jantunen, Esa ^a   Canals, Carmen ^b   Rambaldi, Alessandro ^c   Ossenkoppele, Gert ^d   Allione, Bernardino ^e   Blaise, Didier ^f   Conde, Eulogio ^g   Tilly, Hervè ^h   Cook, Gordon ⁱ   Clark, Fiona ^j   Gallamini, Andrea ^k   Haynes, Andrew ^l   Mounier, Nicolas ^m   Dreger, Peter ⁿ   Pfreundschuh, Michael ^o   Sureda, Anna ^p  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b BANC DE SANG I TEIXITS   (Spain)

^c Bergamo Hospital   (Italy)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e H SS Antonio e Biagio   (Italy)

^f INSTITUT PAOLI CALMETTES   (France)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^j Centre for Clinical Haematology   (United Kingdom)

^k S CROCE E CARLE HOSPITAL   (Italy)

^l NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^m CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o SAARLAND UNIVERSITY   (Germany)

^p HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

Autologous stem cell transplantation; Diffuse large B cell lymphoma; Elderly patients; Non relapse mortality; Outcome

Indexed keywords

ADULT; ARTICLE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; REGISTRIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 57349199069     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13273     Document Type: Article

References (27)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235-42.
2. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of DSHNHL. Blood 2004;104:634-41.
3. Philip T, Guglielmi C, Hagenbeek A, Somerts R, van dert Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared to salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
4. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-30.
5. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-7.
6. Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287-95.
7. Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation in slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995;332:1045-51.
8. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: a randomised phase III EORTC study. J Natl Cancer Inst 2001;93:22-30.
9. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P, et al. Shortened first-line high-dose chemotherapy for patients with poorprognosis aggressive lymphoma. J Clin Oncol 2002;20:2472-9.
10. Kaiser U, Uebelacker I, Abel U, Birkmann J, Truemper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as a part of primary treatment for 'aggressive' lymphoma. J Clin Oncol 2002;20:4413-9.
11. Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Cantonetti M, et al. Early autologous stem cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian randomized multicenter trial. J Clin Oncol 2003;21: 1255-62.
12. Moreau P, Milpied N, Voillat L, Colombat P, Mahe B, Rapp MJ, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61-65 years: a pilot study. Bone Marrow Transplant 1998;21:1193-6.
13. Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L. Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000;6:204-10.
14. Jantunen E, Mahlamäki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (≥60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 2000;26:737-41.
15. Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A, et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for haematological malignancies: a single centre experience. Bone Marrow Transplant 2001;27:1189-95.
16. Zallio F, Cuttica A, Caracciolo D, Gavarotti P, Bergui L, Giaretta F, et al. Feasibility of peripheral blood progenitor cell mobilisation and harvest to support chemotherapy intensification in elderly patients with poor prognosis non-Hodgkin's lymphoma. Ann Hematol 2002;81:448-53.
17. Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D, et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation in elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003;9:383-8.
18. Villela L, Sureda A, Canals C, Sanz MA Jr, Martino R, Valcarcel D, et al. Low transplant-related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003;88:300-5.
19. Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001;27:593-9.
20. Jantunen E, Itälä M, Juvonen E, Leppä S, Keskinen L, Vasala K, et al. Autologous stem cell transplantation in elderly (≥60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37:367-72.
21. Buadi FK, Micallef IN, Ansell SM, Porrata LF, Dispenzieri A, Elliot MA, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006;37:1017-22.
22. Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, et al. High-dose chemotherapy and autologous progenitor cell transplantation for non-Hodgkin's lymphoma patients >65 years of age. Ann Oncol 2008;19:1166-71.
23. Kuittinen T, Wiklund T, Remes K, Elonen E, Lehtinen T, Kuitttinen O, et al. Outcome of progressive disease after autologous stem cell transplantation in patients with non-Hodgkin's lymphoma: a nationwide survey. Eur J Haematol 2005;75:199-205.
24. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantatation (HCT)-specific co-morbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-9.
25. Artz AS, Pollyea DA, Kocherginsky M, Stock W, Rich E, Odenike O, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006; 12:954-64.
26. Jantunen E. Autologous stem cell transplantation beyond 60 years of age. Bone Marrow Transplant 2006;38:715-20.
27. Gopal AK, Rajendran JG, Gooley TA, Pagel JM, Fisher DR, Petersdorf SH, et al. High-dose 131-tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults >60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007;25:1396-402.